Skip to content
AnalystLens

Roivant SciencesROIV

Legal name
Roivant Sciences Ltd.
Sector
Healthcare
Industry
Pharmaceutical Preparations
Exchange
Nasdaq

Stock Price $ROIV

Latest filings

You are here#47 of 54 in Healthcare by market cap

Filing record · 2021–202610-K510-Q168-K82

ROIV filed 5 annual reports (10-K), 16 quarterly reports (10-Q) and 82 current reports (8-K) between 2021 and 2026.

  1. Leadership change8-K · Oct ’21Oct ’21
  2. Leadership change8-K · Nov ’22Nov ’22
  3. Deal closed8-K · Dec ’23Dec ’23
  4. FY2026 annual report10-K · May ’26May ’26

01—Key figures

Source: 10-KFY2026
Source: 10-KFY2026
Source: 10-KFY2026
Source: 10-KFY2026

Revenue Trend

Year-over-year comparison from 10-K annual reports

  6. $8.3M
YoY changeLargest recent move+132.3%in FY22Latest −71.6%

Latest bar from 10-KFY2026Click a bar to open its SEC filing

View full history →
All ROIV Financial Metrics56 metrics

Income Statement15

Balance Sheet26

Cash Flow11

Per Share4

02—Overview

Roivant Sciences Financial Overview 2022–2026

Updated Nov 4, 2026

Roivant sold a single subsidiary for a $5.35 billiona gain in FY2024, then spent the next two years burning through the proceeds while building a pipeline that has started to deliver. That is the core thesis: the cash pile is funding a transition from a one-product company to a late-stage immunology developer, and the clinical data is now catching up to the spending.

The long-term arc is stark. Revenue went from $55.3 million in FY2022 to $29.1 millionb in FY2025, as the sale of Dermavant removed VTAMA, the only commercial product. Cash moved the other way, from about $2.1 billion at the end of FY2022 to $4.3 billion at the end of FY2026, after peaking near $6.6 billion in FY2024. Operating costs keep climbing. R&D reached $681.8 million in FY2026, up from $550.4 million, while G&A held at $610.5 million. The FY2026 net loss was $299.8 million, softened by a $770.2 million gain on the Moderna settlement. Buybacks were large: $1.3 billion in FY2025 cut shares outstanding by 14%.

The market has noticed. Roivant closed at $10.09c at the end of FY2025, a $7.0 billion market cap, then at $27.70 at the end of FY2026, a $20.0 billion market cap. Neither period had positive earnings, with EPS of -$0.24 and -$0.54. Investors are paying for pipeline outcomes, not profits.

Recent Developments (Q4 2026 and Q1 2027)

The FDA approved LISRAYA (brepocitinib) for dermatomyositis on August 26, 2026, with launch the next day at a $35,000d list price per 30-count bottle, ahead of the September target. In VALOR, 55% of treated patients met the response and steroid-sparing endpoint versus 30% on placebo. Mosliciguat then hit its PHocus Phase 2 endpoint, cutting pulmonary vascular resistance 56.3% versus placebo. On October 20, brepocitinib succeeded in two Phase 3 uveitis trials, with hazard ratios of 0.27 and 0.22. Quarterly operating cash outflow rose to $270.5 million in Q1 FY2027, and the Q1 net loss was $290.6 million.

Bulls see a launched product, a second sNDA filing planned for 1H 2027, and a Phase 3 asset in PH-ILD. Bears point to the boxed warning, rising burn, and a valuation of $25.8 billione market cap at $35.78 as of August 5, 2026, with trailing EPS of -$0.54 and no meaningful P/E.

What to watch: LISRAYA launch uptake and the December 9 investor day; Moderna's Section 1498 appeal and the contingent $1.3 billion

03—Filings

Recent SEC Filings

  1. 8-KRoivant Sciences 8-K Report, Regulation FD Disclosure (Oct 21, 2026)Roivant Sciences Ltd. (ROIV) reported, via a press release furnished as Exhibit 99.1 to this Form 8-K, positive results from the Phase 3 CLARITY-1 and CLARITY-2 trials evaluating brepocitinib 45 mg once daily in non-infectious uveitis (NIU). The trials were conducted by its subsidiary Priovant Therapeutics, Inc. Brepocitinib achieved statistically significant benefit versus placebo on the primary endpoint (time to treatment failure) and all key secondary endpoints in both studies. Median time to treatment failure was greater than 48 weeks in both studies versus about 12 weeks on placebo (p<0.0001 in both). Pooled across the studies, 62% of brepocitinib patients achieved steroid-free quiescence at Week 48 versus 20% on placebo. The filing reports that 42% of eyes on brepocitinib achieved resolution of macular edema at Week 48 versus 4.8% on placebo (pooled, among patients with macular edema at baseline). Safety was described as consistent with prior brepocitinib trials with no new safety signals, and only 3% of participants discontinued treatment due to an adverse event. Priovant intends to file a supplemental New Drug Application for NIU in the first half of calendar 2027. The company also plans an investor call on October 21, 2026 and an investor day on December 9, 2026. The company describes brepocitinib, already approved as LISRAYA for adult dermatomyositis, as potentially the most effective systemic, non-steroid treatment option for NIU. Management's characterization of the results as a potential new standard of care is company-generated and the filing does not provide regulatory review outcomes or commercial projections.
  2. 8-KRoivant Sciences 8-K Report, Shareholder Vote Results (Sep 18, 2026)Roivant Sciences Ltd. held its 2026 Annual General Meeting of Shareholders on September 16, 2026. Holders of record of 652,143,869 common shares, representing approximately 90.3% of the 722,406,273 shares outstanding and entitled to vote as of the July 23, 2026 record date, were present in person or by proxy, which constituted a quorum. The filing states that all proposals on the agenda were approved. The matters are described in more detail in the proxy statement filed with the SEC on July 29, 2026. Shareholders re-elected Daniel Gold and Meghan FitzGerald as Class II directors, each to serve until the annual general meeting following the fiscal year ending March 31, 2029. Shareholders also ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending March 31, 2027, and as its statutory auditor under the Bermuda Companies Act 1981. The ratification received 651,315,490 votes for, 731,364 against and 97,015 abstentions. On a non-binding advisory basis, shareholders approved the compensation of the company's named executive officers. The vote recorded 316,702,500 for, 269,062,122 against, 230,600 abstentions and 66,148,647 broker non-votes. The filing also lists a Cover Page Interactive Data File (Exhibit 104) as the only exhibit.
  3. 8-KRoivant Sciences 8-K Report, Regulation FD Disclosure (Sep 8, 2026)Roivant Sciences Ltd. (ROIV) furnished a Form 8-K under Item 7.01 (Regulation FD Disclosure) announcing positive results from the Phase 2 PHocus clinical trial of mosliciguat, an inhaled sGC activator being developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The trial was conducted by its subsidiary, Pulmovant, Inc., and the results were presented at the European Respiratory Society International Congress 2026. The study met its primary endpoint, with a placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% at Week 16 (p<0.0001), and met its secondary endpoints of a placebo-adjusted improvement in six-minute walk distance (+35.2 meters, p=0.0027) and a placebo-adjusted reduction in NT-proBNP of -357.7 pg/mL (p=0.0002) at Week 16. In a pre-specified exploratory analysis, placebo-adjusted improvements at Week 24 reached +52.7 meters in 6MWD and -487.1 pg/mL (-75.9%) in NT-proBNP, both with nominal p<0.0001. The company reported that mosliciguat was well tolerated, with cough reported in 12.1% of mosliciguat patients versus 18.2% of placebo patients. The company also announced that the Phase 3 PHrontier study, designed to enroll approximately 375 patients, has been initiated and enrollment is underway. The filing is a furnished (not filed) disclosure, and the press release contains forward-looking statement language. Investors should note that the results are from a Phase 2 trial with a relatively small sample of 135 patients across 87 sites in 20 countries, and that the Phase 3 study is ongoing.
  4. 8-KRoivant Sciences 8-K Report, Corporate Update (Aug 28, 2026)Roivant Sciences Ltd. (ROIV) filed this Form 8-K on August 28, 2026 to report that the U.S. Food and Drug Administration approved LISRAYA (brepocitinib) for the treatment of adults with dermatomyositis (DM). The company posted an investor presentation on its investor relations website, filed as Exhibit 99.1. The filing states a wholesale acquisition cost of $35,000 for a 30-count bottle of 30 mg tablets. According to the presentation, LISRAYA is commercially available immediately upon approval, ahead of prior guidance calling for a launch by the end of September 2026. The presentation cites Phase 3 VALOR results, in which the 30 mg dose reached a mean Total Improvement Score (TIS) of 46.5 versus 31.2 for placebo at Week 52 (p = 0.0006), and TIS40 response rates of 67.9% versus 44.3%. The product carries a JAK-class boxed warning covering serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. The presentation also describes a limited specialty pharmacy distribution network and expects adoption to build gradually given long-established prescribing patterns in DM. The presentation states that Priovant, a Roivant subsidiary, holds commercial rights to brepocitinib in the U.S. and Japan, and that Roivant owned 71% of Priovant as of June 30, 2026, with Pfizer owning 24%. Other pipeline indications for brepocitinib, including non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris, remain investigational.
  5. 8-KRoivant Sciences 8-K Report, Regulation FD Disclosure (Aug 27, 2026)Roivant Sciences Ltd. (Nasdaq: ROIV) announced in an 8-K filed August 27, 2026 that the U.S. Food and Drug Administration has approved LISRAYA™ (brepocitinib) 30 mg, a once-daily pill, for the treatment of adults with dermatomyositis (DM). The New Drug Application was submitted by the company's subsidiary, Priovant Therapeutics, Inc. The press release states the drug is available immediately in the U.S. through a limited specialty pharmacy distribution network, and that eligible patients may pay as little as $0 per month through the LISRAYA My Compass Support program. The filing cites results from the Phase 3 VALOR trial, which the company describes as the largest DM trial ever conducted. Per the release, 55% of LISRAYA-treated patients achieved moderate or better improvement on the myositis Total Improvement Score and minimal or no steroid use by the end of the 52-week study, compared with 30% on placebo. Among patients taking at least 7.5 mg/day of oral corticosteroids at baseline, 62% tapered to 2.5 mg/day or less, compared with 38% on placebo. The label carries a boxed warning covering serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. The company also stated that its late-stage programs in non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris continue, and that it will host an investor conference call at 8:00 a.m. ET on August 28, 2026. The press release is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.
View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →

04—See also

Related Companies

Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.